Thrombin-activatable fibrinolysis inhibitor: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
(No difference)
|
Latest revision as of 16:53, 20 August 2012
carboxypeptidase B2 | |
---|---|
Identifiers | |
Symbol | CPB2 |
Entrez | 1361 |
HUGO | 2300 |
OMIM | 603101 |
RefSeq | NM_001872 |
UniProt | Q96IY4 |
Other data | |
Locus | Chr. 13 q14.11 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.
TAFI is produced by the liver.